The Pattern of Elevated Liver Function Tests in Nonalcoholic Fatty Liver Disease Predicts Fibrosis Stage and Metabolic-Associated Comorbidities.


Journal

Digestive diseases (Basel, Switzerland)
ISSN: 1421-9875
Titre abrégé: Dig Dis
Pays: Switzerland
ID NLM: 8701186

Informations de publication

Date de publication:
2019
Historique:
received: 21 02 2018
accepted: 21 06 2018
pubmed: 18 7 2018
medline: 26 12 2018
entrez: 18 7 2018
Statut: ppublish

Résumé

Patients with nonalcoholic fatty liver disease (NAFLD) and with abnormal liver function tests (LFTs) most commonly present with elevated hepatocellular enzymes (H pattern), but a subset of patients is found to have elevated cholestatic enzymes (C pattern) or a mixed (M) pattern. To determine whether the epidemiologic background and comorbidities, as well as the degree of liver fibrosis, differ between NAFLD patients with different patterns of elevated LFTs by retrospectively analyzing data of 106 patients with a biopsy-proven diagnosis of NAFLD. The pattern of elevated LFTs was determined by adopting the "R-Ratio" formula commonly used for drug-induced liver injury. Advanced fibrosis (F > 2) was found in 15 out of 48 (31.3%) patients with a C pattern of elevated LFTs as compared to 2 out of 44 (4.5%) in M patients and 2 out of 11 (18.2%) in H patients (p = 0.004). Group C patients are older and also had a higher prevalence of diabetes, a higher mean hemoglobin A1c, and a higher prevalence of hypertension, as well as a trend for a higher prevalence of hypertriglyceridemia. Using a simple formula incorporating routine LFTs can help to categorize NAFLD patients as low or high risk for advanced fibrosis stage and metabolic-associated comorbidities.

Sections du résumé

BACKGROUND BACKGROUND
Patients with nonalcoholic fatty liver disease (NAFLD) and with abnormal liver function tests (LFTs) most commonly present with elevated hepatocellular enzymes (H pattern), but a subset of patients is found to have elevated cholestatic enzymes (C pattern) or a mixed (M) pattern.
AIMS AND METHODS OBJECTIVE
To determine whether the epidemiologic background and comorbidities, as well as the degree of liver fibrosis, differ between NAFLD patients with different patterns of elevated LFTs by retrospectively analyzing data of 106 patients with a biopsy-proven diagnosis of NAFLD. The pattern of elevated LFTs was determined by adopting the "R-Ratio" formula commonly used for drug-induced liver injury.
RESULTS RESULTS
Advanced fibrosis (F > 2) was found in 15 out of 48 (31.3%) patients with a C pattern of elevated LFTs as compared to 2 out of 44 (4.5%) in M patients and 2 out of 11 (18.2%) in H patients (p = 0.004). Group C patients are older and also had a higher prevalence of diabetes, a higher mean hemoglobin A1c, and a higher prevalence of hypertension, as well as a trend for a higher prevalence of hypertriglyceridemia.
CONCLUSIONS CONCLUSIONS
Using a simple formula incorporating routine LFTs can help to categorize NAFLD patients as low or high risk for advanced fibrosis stage and metabolic-associated comorbidities.

Identifiants

pubmed: 30016799
pii: 000491428
doi: 10.1159/000491428
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

69-76

Informations de copyright

© 2018 S. Karger AG, Basel.

Auteurs

Dor Shirin (D)

Department of Medicine D, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel.

Noam Peleg (N)

Department of Medicine D, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel.
The Liver Institute, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel.

Orly Sneh-Arbib (O)

The Liver Institute, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel.

Michal Cohen-Naftaly (M)

The Liver Institute, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel.

Marius Braun (M)

The Liver Institute, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel.
The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Tzipora Shochat (T)

Biostatistics Core, Rabin Medical Center, Petah-Tikva, Israel.

Assaf Issachar (A)

Department of Medicine D, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel.
The Liver Institute, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel.

Amir Shlomai (A)

Department of Medicine D, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israelshlomaiamir@gmail.com.
The Liver Institute, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israelshlomaiamir@gmail.com.
The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israelshlomaiamir@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH